Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

BMS: Sales For Opdivo Are Flying High

This article was originally published in Scrip

Executive Summary

Recent approvals for Bristol-Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) resulted in accelerated sales in the second half, with rapid adoption in new indications, said CEO Giovanni Caforio at the J.P. Morgan conference in San Francisco this week.

Advertisement

Related Content

Bristol Getting Eagerly Awaited First-Line Opdivo Lung Data Earlier Than Expected

Topics

Advertisement
UsernamePublicRestriction

Register